Dendreon Corp fka DNDNQ

[Bruce A Thompson]

Dendreon (NASDAQ: DNDN ) was approved in 2010, it was expected to change the face of advanced prostate cancer treatment. The three-course treatment involves removing immune cells from a patients' blood, exposing them to a commonly found cancer protein, and then reinjecting them into the patients' prostate with the expectation that they'll attack the prostate cancer cells. In clinical trials, median overall survival time rose 4.1 months to 25.8 months versus 21.7 months for the placebo. Unfortunately for Dendreon, sales have lagged because its $93,000 price tag has made physicians and patients leery of potentially not being reimbursed. Insurers, as well, have been slow to latch onto the treatment.

http://www.fool.com/investing/general/2013/03/05/tackling-cancer-prostate-cancers-biggest-current-u.aspx